New York, March 02, 2015 -- Moody's Investors Service affirmed Boston Scientific Corporation's Baa3 senior unsecured debt ratings following the company's announcement that it intends to purchase Endo's AMS Men's Health business for about $1.6 billion, which will be funded entirely with debt. The rating outlook is stable.

Vollständigen Artikel bei Moodys lesen